Suppr超能文献

两篇早产儿氧饱和度目标值试验的结局。

Outcomes of Two Trials of Oxygen-Saturation Targets in Preterm Infants.

出版信息

N Engl J Med. 2016 Feb 25;374(8):749-60. doi: 10.1056/NEJMoa1514212. Epub 2016 Feb 10.

Abstract

BACKGROUND

The safest ranges of oxygen saturation in preterm infants have been the subject of debate.

METHODS

In two trials, conducted in Australia and the United Kingdom, infants born before 28 weeks' gestation were randomly assigned to either a lower (85 to 89%) or a higher (91 to 95%) oxygen-saturation range. During enrollment, the oximeters were revised to correct a calibration-algorithm artifact. The primary outcome was death or disability at a corrected gestational age of 2 years; this outcome was evaluated among infants whose oxygen saturation was measured with any study oximeter in the Australian trial and those whose oxygen saturation was measured with a revised oximeter in the U.K. trial.

RESULTS

After 1135 infants in Australia and 973 infants in the United Kingdom had been enrolled in the trial, an interim analysis showed increased mortality at a corrected gestational age of 36 weeks, and enrollment was stopped. Death or disability in the Australian trial (with all oximeters included) occurred in 247 of 549 infants (45.0%) in the lower-target group versus 217 of 545 infants (39.8%) in the higher-target group (adjusted relative risk, 1.12; 95% confidence interval [CI], 0.98 to 1.27; P=0.10); death or disability in the U.K. trial (with only revised oximeters included) occurred in 185 of 366 infants (50.5%) in the lower-target group versus 164 of 357 infants (45.9%) in the higher-target group (adjusted relative risk, 1.10; 95% CI, 0.97 to 1.24; P=0.15). In post hoc combined, unadjusted analyses that included all oximeters, death or disability occurred in 492 of 1022 infants (48.1%) in the lower-target group versus 437 of 1013 infants (43.1%) in the higher-target group (relative risk, 1.11; 95% CI, 1.01 to 1.23; P=0.02), and death occurred in 222 of 1045 infants (21.2%) in the lower-target group versus 185 of 1045 infants (17.7%) in the higher-target group (relative risk, 1.20; 95% CI, 1.01 to 1.43; P=0.04). In the group in which revised oximeters were used, death or disability occurred in 287 of 580 infants (49.5%) in the lower-target group versus 248 of 563 infants (44.0%) in the higher-target group (relative risk, 1.12; 95% CI, 0.99 to 1.27; P=0.07), and death occurred in 144 of 587 infants (24.5%) versus 99 of 586 infants (16.9%) (relative risk, 1.45; 95% CI, 1.16 to 1.82; P=0.001).

CONCLUSIONS

Use of an oxygen-saturation target range of 85 to 89% versus 91 to 95% resulted in nonsignificantly higher rates of death or disability at 2 years in each trial but in significantly increased risks of this combined outcome and of death alone in post hoc combined analyses. (Funded by the Australian National Health and Medical Research Council and others; BOOST-II Current Controlled Trials number, ISRCTN00842661, and Australian New Zealand Clinical Trials Registry number, ACTRN12605000055606.).

摘要

背景

早产儿氧饱和度的安全范围一直存在争议。

方法

在澳大利亚和英国进行的两项试验中,胎龄小于 28 周的婴儿被随机分配到较低(85 至 89%)或较高(91 至 95%)的氧饱和度范围。在入组期间,对血氧计进行了修订以纠正校准算法的误差。主要结局是校正胎龄 2 岁时的死亡或残疾;在澳大利亚试验中用任何研究血氧计测量的婴儿中评估了这一结局,而在英国试验中用修订后的血氧计测量的婴儿中评估了这一结局。

结果

在澳大利亚的 1135 名婴儿和英国的 973 名婴儿入组后,中期分析显示校正胎龄 36 周时死亡率增加,入组停止。在澳大利亚试验中(包括所有血氧计),较低目标组 549 名婴儿中有 247 名(45.0%)发生死亡或残疾,而较高目标组 545 名婴儿中有 217 名(39.8%)(调整后相对风险,1.12;95%置信区间[CI],0.98 至 1.27;P=0.10);在英国试验中(仅包括修订后的血氧计),较低目标组 366 名婴儿中有 185 名(50.5%)发生死亡或残疾,而较高目标组 357 名婴儿中有 164 名(45.9%)(调整后相对风险,1.10;95%置信区间[CI],0.97 至 1.24;P=0.15)。在包括所有血氧计的事后综合、未调整分析中,较低目标组 1022 名婴儿中有 492 名(48.1%)发生死亡或残疾,而较高目标组 1013 名婴儿中有 437 名(43.1%)(相对风险,1.11;95%置信区间[CI],1.01 至 1.23;P=0.02),较低目标组 1045 名婴儿中有 222 名(21.2%)死亡,而较高目标组 1045 名婴儿中有 185 名(17.7%)(相对风险,1.20;95%置信区间[CI],1.01 至 1.43;P=0.04)。在使用修订后的血氧计的组中,较低目标组 580 名婴儿中有 287 名(49.5%)发生死亡或残疾,而较高目标组 563 名婴儿中有 248 名(44.0%)(相对风险,1.12;95%置信区间[CI],0.99 至 1.27;P=0.07),较低目标组 587 名婴儿中有 144 名(24.5%)死亡,而较高目标组 586 名婴儿中有 99 名(16.9%)(相对风险,1.45;95%置信区间[CI],1.16 至 1.82;P=0.001)。

结论

与 91 至 95%的氧饱和度目标范围相比,使用 85 至 89%的氧饱和度目标范围在每个试验中并没有显著增加 2 岁时死亡或残疾的发生率,但在事后综合分析中,这一综合结局和单独死亡的风险显著增加。(由澳大利亚国家卫生和医学研究委员会等资助;BOOST-II 当前对照试验编号,ISRCTN00842661,和澳大利亚新西兰临床试验注册编号,ACTRN12605000055606。)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验